With support and innovation from the State’s universities and world-class research institutes, Delaware’s bioscience industry is one of the strongest in the nation.
Delaware’s bioscience sector is among the country’s fastest-growing, as pharmaceutical, agricultural, chemical, medical device and diagnostics and advanced materials companies combine with the state’s universities and research institutes to move cutting-edge technology from the lab to the marketplace.
Eighty percent of the U.S. pharmaceuticals industry is headquartered in the region, where firms collaborate with research and medical institutions to develop and commercialize many of the innovative drugs, diagnostics and medical devices currently going to market.
The State’s competitive edge is enhanced by an experienced and skilled workforce, access to state-of-the-art academic and research institutions such as the Delaware Biotechnology Institute (DBI), the Fraunhofer USA Center for Molecular Biotechnology and the University of Delaware’s Department of Chemical & Biomolecular Engineering (consistently ranked among the top ten nationwide by U.S. News and World Report), lab space availability, a supportive business community and high quality of life for bioscience professionals.
The DBI is a magnet for life science R&D, fostering academic-industrial research partnerships between the local bioscience industry and the Delaware Bioscience Association. The Institute’s laboratories see scientists, students and faculty researching agriculture, health and energy and the environment, and its high-end instrumentation facilities are available to Delaware’s life science community.
Delaware Bio is a non-profit trade association focused solely on promoting Delaware’s growing bioscience industry. Its mission is to serve as a catalyst to ensure Delaware becomes a global leader in life sciences by developing a cohesive community that unites the region’s biotechnology, pharmaceutical, research, financial and agricultural strengths.
The Gene Editing Institute and NovellusDx will use the grant money to research a new series of state-of-the-art gene editing technologies that help identify the genetic mechanism responsible for both the onset and progression of many types of cancer. The two organizations are collaborating on a licensing agreement to commercialize the gene editing technologies that result from the research.
The University of Delaware has been selected as the site of a new Biopharma Manufacturing USA Institute. The Institute will comprise a group of 150 companies, colleges, nonprofits and government agencies, and will receive $200 million in funding.
Related Topics: ANP Technologies, Bioscience, chemical, Delaware BioScience Association, Delaware Bioscience Industry, Delaware Biotechnology Institute, Delaware Key Industries, Fraunhofer USA Center for Molecular Biology, Invest, key industries, NASA, Optical Science Center for Applied Research, OSCAR, pharmaceuticals, Ray Yin, research